Pharma firm ‘discovers antibody that blocks 100% of coronavirus infections and flushes out bug in FOUR DAYS’ – The Sun

A BIOTECH company claims to have found an antibody that can make a person immune to COVID-19 – and cure the virus in days.

Sorrento Therapeutics CEO Henry Ji announced the breakthrough on Friday, revealing the company is “working day and night to complete the steps necessary to get this product approved."

Researchers at Sorrento discovered the "cure", STI-1499, after analyzing billions of antibodies to see how they interact with coronavirus.

Scientists found STI-1499 binds itself to the coronavirus, stops it from multiplying and removes it from the human body in four days.

When present in the body of a person who does not have COVID-19, it provides immunity, the company claims.

“We want to emphasize there is a cure,” Ji said an interview with Fox News.

He also explained how the STI-1499 antibody allegedly ‘cures’ the virus.

"When the antibody prevents a virus from entering a human cell, the virus cannot survive," Dr. Ji said.

"If they cannot get into the cell, they cannot replicate. So it means that if we prevent the virus from getting the cell, the virus eventually dies out. The body clears out that virus."

“[STI-1499] puts its arms around the virus. It wraps around the virus and moves them out of the body."

“There is a solution that works 100 percent,” he insisted. “If we have the neutralizing antibody in your body, you don't need the social distancing. You can open up a society without fear."

Shares of Sorrento, based in San Diego, rose up 138.6% within hours of the announcement.

Last week Sorrento partnered with New York City's Mount Sinai Health System to develop the antibody cocktail, with the aim of starting human trials in the third quarter, Reuters reported.

There are currently no treatments or vaccines approved for the coronavirus and several drugmakers have been rushing to develop new treatments or repurpose existing drugs to treat patients.

The collaboration with Mount Sinai gives Sorrento access to a pool of antibodies against COVID-19 obtained from nearly 15,000 individuals screened by the hospital group.

Sorrento, which has several treatments in development, including four immuno-oncology therapies, said it is completing the requirements for its application to the U.S. Food and Drug Administration to begin early-stage testing in humans.

Source: Read Full Article